Search | Clinical Trials Finder

Conditions: Complications; Cesarean Section, Spinal Anesthetics Causing Adverse Effects in Therapeutic Use
Interventions: Phenylephrine; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Anesthesia
Interventions: Tetracaine HCl 3% and oxymetazoline HCl 0.05%, Tetracaine HCl 3%, Placebo; Drug
Lead sponsor: St. Renatus, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 3
States / cities: Baltimore, Maryland • Salt Lake City, Utah

Conditions: Sleep Apnea, Chronic Nasal Congestion
Interventions: Oxymetazoline Hydrochloride, Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Syncope, Vasovagal
Interventions: CPC - Capsaicin, Phenylephrine, Caffeine, Tilt Table Test, Placebo; Drug · Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 50 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Mydriasis
Interventions: Tropicamide/Phenylephrine ophthalmic solution (TR/PE), Placebo; Drug
Lead sponsor: Eyenovia Inc.; Industry
Eligibility: Not listed
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Austin, Texas • San Antonio, Texas

Conditions: Autonomic Failure, Orthostatic Hypotension
Interventions: Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham); Drug · Other · Dietary Supplement + 1 more
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Transient Insomnia
Interventions: SM-1, D+Z, D+L, Placebo; Drug
Lead sponsor: Sequential Medicine Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Healthy
Interventions: Silenor 6 mg, zolpidem 10 mg, Placebo; Drug
Lead sponsor: Currax Pharmaceuticals; Industry
Eligibility: 21 Years to 50 Years · Male only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Novi, Michigan

Conditions: Allergic Conjunctivitis
Interventions: Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%, Oxymetazoline HCl 0.025%; Drug
Lead sponsor: Eye Therapies, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Narcolepsy
Interventions: JZP441, Matching Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Atlanta, Georgia • Cincinnati, Ohio • Columbia, South Carolina + 1 more

Conditions: Intraocular Lens Replacement
Interventions: OMS302, Placebo; Drug
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: Chandler, Arizona • Los Angeles, California • Fort Myers, Florida + 10 more

Conditions: ADHD, Narcolepsy
Interventions: ADAIR 10 mg IR tablets, d-amphetamine sulfate, Placebo; Drug
Lead sponsor: Vallon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Subjects
Interventions: placebo, lorazepam, GW876008; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Allergic Rhinitis
Interventions: Fluticasone furoate, Placebo Fluticasone furoate, Oxymetazoline, Placebo Oxymetazoline; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
Interventions: NKTR-118, moxifloxacin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Obstetric Labour, Premature
Interventions: Retosiban 100 mg, Retosiban 800 mg, Placebo, Moxifloxacin 400 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hyperuricemia, Gout, Qt Interval, Variation in
Interventions: LC350189 200mg, Placebo, Moxifloxacin 400mg, LC350189 600mg; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteer
Interventions: Part 1: SAD RO7033877, Part 1: SAD placebo, Part 2: Treatment A, RO7033877, Part 2: Treatment B, RO7033877, Part 2: Treatment C, moxifloxacin, Part 2: Treatment D, RO7033877 and moxifloxacin placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Intraocular Lens Replacement
Interventions: OMS302, Placebo; Drug
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 16
States / cities: Chandler, Arizona • Glendale, Arizona • Los Angeles, California + 13 more

Conditions: Anesthesia
Interventions: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%, Placebo spray; Drug
Lead sponsor: St. Renatus, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Mydriasis, Dilation
Interventions: Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle; Drug
Lead sponsor: Ocuphire Pharma, Inc.; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Longwood, Florida • Athens, Ohio

Conditions: Healthy Volunteer
Interventions: RO4917523, escitalopram, methylphenidate, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Blepharoptosis
Interventions: RVL-1201, RVL-1201 Vehicle Placebo; Drug
Lead sponsor: RVL Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Morrow, Georgia

Conditions: Epistaxis, Blood Pressure
Interventions: Oxymetazoline 0.05%, Phenylephrine 0.25%, Lidocaine 1% plus epinephrine 1:100,000, Bacteriostatic 0.9% NaCL; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Phenylephrine Dose and Mode of Administration for Spinal Anesthesia Induced Hypotension

Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth

Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

Treatment of Orthostatic Hypotension in Autonomic Failure

SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.

Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers

A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)

A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1

Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)

A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.

Intranasal Steroids and Oxymetazoline in Allergic Rhinitis

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.

Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects

A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval

Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

Comparison of Anesthetic Efficacy of Bilateral and Unillateral Application of Kovacaine Mist in Healthy Volunteers

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers

Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis

The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.